Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

As a key component of the standard of care for glioblastoma, radiotherapy induces several
immune resistance mechanisms, such as upregulation of CD47 and PD-L1. Here …

Cellular heterogeneity and an immunosuppressive tumour microenvironment are
independent yet synergistic drivers of tumour progression and underlie therapeutic …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

The chemokine ligand CCL2 and its receptor CCR2 are implicated in the initiation and
progression of various cancers. CCL2 can activate tumour cell growth and proliferation …

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective
responses in adults with glioblastoma, but the feasibility and tolerability of this approach is …

Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …

Immune cell infiltration into solid tumors, their movement within the tumor microenvironment
(TME), and interaction with other immune cells are controlled by their directed migration …